Syra Health (SYRA) Q2 2026 earnings summary

Executive summary

• Achieved strong revenue growth and returned to profitability for the quarter and six months ended June 30, 2026, driven by increased healthcare workforce and population health contracts.

• Launched Syrenity, an AI-driven behavioral and mental health application, and expanded digital health offerings.

• Continued focus on cost control, operational streamlining, and strategic expansion in government and commercial healthcare markets.

• Gross margin reached a record 44.5%, up from 38.7% in Q2 2025.

• EBITDA improved to $253,200 from a loss of $53,760 year-over-year.

Financial highlights

• Net revenues for the six months ended June 30, 2026, were $4.67M, up 23% year-over-year; gross profit increased to $2.04M, with gross margin rising to 44%.

• Net income for the six months was $491,221, compared to a net loss of $535,861 in the prior year period.

• For the quarter, net revenues were $2.4M (up 23% year-over-year), with net income of $250,242 versus a net loss of $63,596 in Q2 2025.

• Net cash provided by operating activities for the six months was $643,183, up from $85,754 year-over-year.

• Cash and cash equivalents at June 30, 2026, were $2.12M; no long-term debt as of June 30, 2026.

Outlook and guidance

• Management anticipates continued revenue growth from contract renewals and new awards, including a one-year extension with Wake County Public Health and Indiana Veterans' Home.

• Approval for the CMS ACCESS Model in partnership with HealthSync is expected to provide a durable revenue stream over the next decade.

• Focus remains on achieving full-year profitability for 2026.

• Ongoing focus on expanding market presence and launching Syrenity in global markets.

• Revenue recognition, timing, and contract milestones expected to contribute to quarterly variability.